Resultados: 1332

    Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted. This technology appraisal is for treating idiopathic pulmonary fibrosis in people with a forced vital capacity (FVC) above 80% predicted. Nintedanib...

    Multidisciplinary guidelines for the rational use of topical non-steroidal anti-inflammatory drugs for musculoskeletal pain (2022)

    J Clin Med; 12 (4), 2023
    Topical non-steroidal anti-inflammatory drugs (NSAIDs) are one of the primary drugs for treating musculoskeletal pain. However, there are currently no evidence-based recommendations about drug selection, drug administration, drug interactions, and use in special populations or other pharmacology-related ...

    Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach

    J Gastric Cancer; 23 (1), 2023
    Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group inclu...

    Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians

    Ann. intern. med; 176 (2), 2023
    Primary care patients and clinicians may prefer alternative options to second-generation antidepressants for major depressive disorder (MDD). To compare the benefits and harms of nonpharmacologic treatments with second-generation antidepressants as first-step interventions for acute MDD, and to compare s...

    Update alert: nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians

    Ann. intern. med; 176 (2), 2023
    This first update alert reports the surveillance results of the living systematic review on “Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians” (1...

    Summary for patients: pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults

    Ann. intern. med; 176 (2), 2023
    Osteoporosis is a disease, common in older age, that makes your bones weaker and can lead to a fracture. People with previous fractures and those who have other risk factors for fractures, including family history of fractures, vitamin D deficiency or low calcium intake, smoking, excessive alcohol intake...

    Maribavir for treating refractory cytomegalovirus infection after transplant

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...

    Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)

    NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. This is because Paion AG did not provide an evidence submission. We will review this decision if the company decides to make a submission....

    Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

    Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults. Commercial arrangements There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can g...